{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:43Z","timestamp":1707524983331},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"DOI":"10.7759\/cureus.37541","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T20:47:46Z","timestamp":1681418866000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Non-cirrhotic Hyperammonemic Encephalopathy in a Patient With Metastatic Gastrointestinal Stromal Tumor"],"prefix":"10.7759","author":[{"given":"Il Seok D","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parinaz","family":"Abiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leland","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.929","article-title":"Cause for confusion: noncirrhotic hyperammonemic encephalopathy","volume":"15","author":"Kalra A","year":"2020","unstructured":"Kalra A, Norvell JP. Cause for confusion: noncirrhotic hyperammonemic encephalopathy. Clin Liver Dis (Hoboken). 2020, 15:223-7. 10.1002\/cld.929","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701509822","article-title":"Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy","volume":"48","author":"Nott L","year":"2007","unstructured":"Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007, 48:1702-11. 10.1080\/10428190701509822","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.9302","article-title":"Hyperammonemic encephalopathy associated with GI stromal tumor","volume":"34","author":"Chiu CG","year":"2016","unstructured":"Chiu CG, Zaghiyan KN, Silberman AW. Hyperammonemic encephalopathy associated with GI stromal tumor. J Clin Oncol. 2016, 34:e51-3. 10.1200\/JCO.2013.48.9302","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-018-0067-6","article-title":"Multi-targeted tyrosine kinase inhibitor-induced hyperammonemic encephalopathy: a report of two cases using pazopanib, sunitinib, and regorafenib","volume":"50","author":"Kongsuphon N","year":"2019","unstructured":"Kongsuphon N, Soukavanitch M, Teeraaumpornpunt N, Konmun J, Ativitavas T, Ngamphaiboon N. Multi-targeted tyrosine kinase inhibitor-induced hyperammonemic encephalopathy: a report of two cases using pazopanib, sunitinib, and regorafenib. J Gastrointest Cancer. 2019, 50:601-3. 10.1007\/s12029-018-0067-6","journal-title":"J Gastrointest Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12160","article-title":"Regorafenib-induced hyperammonemic encephalopathy","volume":"39","author":"Kuo JC","year":"2014","unstructured":"Kuo JC, Parakh S, Yip D. Regorafenib-induced hyperammonemic encephalopathy. J Clin Pharm Ther. 2014, 39:446-8. 10.1111\/jcpt.12160","journal-title":"J Clin Pharm Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q038","article-title":"Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors","volume":"45","author":"Lee NR","year":"2011","unstructured":"Lee NR, Yhim HY, Yim CY, Kwak JY, Song EK. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors. Ann Pharmacother. 2011, 45:e56. 10.1345\/aph.1Q038","journal-title":"Ann Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq164","article-title":"Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor","volume":"41","author":"Matsumoto K","year":"2011","unstructured":"Matsumoto K, Sawaki A, Mizuno N, et al.. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol. 2011, 41:57-62. 10.1093\/jjco\/hyq164","journal-title":"Jpn J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.054","article-title":"Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases","volume":"8","author":"Lora-Tamayo J","year":"2008","unstructured":"Lora-Tamayo J, Palom X, Sarr\u00e1 J, Gasch O, Isern V, Fern\u00e1ndez de Sevilla A, Pujol R. Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases. Clin Lymphoma Myeloma. 2008, 8:363-9. 10.3816\/CLM.2008.n.054","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12054","article-title":"Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour","volume":"38","author":"Shea YF","year":"2013","unstructured":"Shea YF, Chiu WY, Mok MY, Hung IF, Yau CC. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour. J Clin Pharm Ther. 2013, 38:327-9. 10.1111\/jcpt.12054","journal-title":"J Clin Pharm Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12102","article-title":"Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?","volume":"33","author":"Brandi G","year":"2013","unstructured":"Brandi G, de Rosa F, Calz\u00e0 L, et al.. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?. Liver Int. 2013, 33:488-93. 10.1111\/liv.12102","journal-title":"Liver Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2018.0042","article-title":"Hyperammonemic encephalopathy: an unusual presentation of fibrolamellar hepatocellular carcinoma","volume":"26","author":"Thakral N","year":"2020","unstructured":"Thakral N, Simonetto DA. Hyperammonemic encephalopathy: an unusual presentation of fibrolamellar hepatocellular carcinoma. Clin Mol Hepatol. 2020, 26:74-7. 10.3350\/cmh.2018.0042","journal-title":"Clin Mol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3182a32e0e","article-title":"A rare case of sunitinib-induced hyperammonemic encephalopathy and hypothyroidism in metastatic renal cell carcinoma","volume":"23","author":"Pilanc KN","year":"2016","unstructured":"Pilanc KN, Elb\u00fcken F, Ordu \u00c7, et al.. A rare case of sunitinib-induced hyperammonemic encephalopathy and hypothyroidism in metastatic renal cell carcinoma. Am J Ther. 2016, 23:e583-7. 10.1097\/MJT.0b013e3182a32e0e","journal-title":"Am J Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024313","article-title":"Sunitinib-associated hyperammonemic encephalopathy successfully managed with higher intensity conventional hemodialysis: a case report","volume":"100","author":"Haroon S","year":"2021","unstructured":"Haroon S, Ko S, Wong A, Tan PS, Lee E, Lau T. Sunitinib-associated hyperammonemic encephalopathy successfully managed with higher intensity conventional hemodialysis: a case report. Medicine (Baltimore). 2021, 100:e24313. 10.1097\/MD.0000000000024313","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15406\/jcpcr.2015.03.00076","article-title":"Regorafenib-induced hyperammonemic encephalopathy in metastatic colon cancer","volume":"3","author":"Kitamoto H","year":"2015","unstructured":"Kitamoto H, Satake H, Hatachi Y, Tetsuro I, Akihito T. Regorafenib-induced hyperammonemic encephalopathy in metastatic colon cancer. J Cancer Prev Curr Res. 2015, 3:1-4. 10.15406\/jcpcr.2015.03.00076","journal-title":"J Cancer Prev Curr Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000509640","article-title":"Atypical posterior reversible encephalopathy syndrome due to oral tyrosine kinase inhibitor cabozantinib: first case report","volume":"13","author":"Patwari A","year":"2020","unstructured":"Patwari A, Bhatlapenumarthi V, Pascual SK. Atypical posterior reversible encephalopathy syndrome due to oral tyrosine kinase inhibitor cabozantinib: first case report. Case Rep Oncol. 2020, 13:1013-9. 10.1159\/000509640","journal-title":"Case Rep Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219846253","article-title":"Apatinib-induced hyperammonemic encephalopathy","volume":"26","author":"Liu Y","year":"2020","unstructured":"Liu Y, Chen X, Gao X, Chen JX, Chen J. Apatinib-induced hyperammonemic encephalopathy. J Oncol Pharm Pract. 2020, 26:465-70. 10.1177\/1078155219846253","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/133127-a-case-of-non-cirrhotic-hyperammonemic-encephalopathy-in-a-patient-with-metastatic-gastrointestinal-stromal-tumor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:41Z","timestamp":1707508721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/133127-a-case-of-non-cirrhotic-hyperammonemic-encephalopathy-in-a-patient-with-metastatic-gastrointestinal-stromal-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.37541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}